Multidrug therapy in leprosy can prevent relapse--a retrospective study

Area of Science:

• Dermatology
• Infectious Diseases
• Public Health

Background:

• Leprosy treatment has evolved from monotherapy to multidrug therapy (MDT).
• Understanding relapse rates is crucial for assessing treatment efficacy and disease control.
• Previous leprosy treatment regimens had higher relapse rates compared to MDT.

Purpose of the Study:

• To determine the relapse rate of leprosy patients treated with multidrug therapy (MDT).
• To compare MDT's effectiveness against leprosy relapse with historical monotherapy data.
• To evaluate the impact of MDT on leprosy recurrence in West Bengal.

Main Methods:

• Retrospective study at a Leprosy Control Unit (LCU) in Durgapur, West Bengal.
• Analyzed 1581 patients who completed MDT (PB and MB cases) over 5 years.
• Compared MDT outcomes with pre-MDT monotherapy data from Durgapur LCU and Gopalpur Leprosy Clinic.

Main Results:

• No relapse cases were observed in patients treated with MDT during WHO-recommended surveillance periods.
• Monotherapy at Durgapur LCU showed a 12.4% relapse rate, and Gopalpur Leprosy Clinic had a 10.06% relapse rate.
• MDT demonstrated a zero relapse rate for both paucibacillary (PB) and multibacillary (MB) leprosy.

Conclusions:

• Multidrug therapy (MDT) is highly effective in preventing leprosy relapses.
• MDT offers a significant improvement over historical monotherapy in leprosy management.
• The findings reinforce MDT's role in achieving leprosy eradication goals.